SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+metastatic breast cancer (MBC).

被引：7
|
作者：
Rugo, Hope S.
Pegram, Mark D.
Gradishar, William John
Cortes, Javier
Curigliano, Giuseppe
Wigginton, Jon M.
Lechleider, Robert Joseph
Cardoso, Fatima
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94132 USA
[2] Stanford Sch Med, Stanford, CA 94305 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Vall Hebron Inst Oncol, Barcelona, Spain
[5] Ist Europeo Oncol, Milan, Italy
[6] MacroGen Inc, Rockville, MD USA
[7] Champalimaud Canc Ctr, Lisbon, Portugal
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS630
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+metastatic breast cancer
    Rugo, H. S.
    Pegram, M. D.
    Gradishar, W. J.
    Cortes, J.
    Curigliano, G.
    Hong, S.
    Wigginton, J. M.
    Lechleider, R. J.
    Cardoso, F.
    CANCER RESEARCH, 2017, 77
  • [2] SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) plus Ctx versus trastuzumab (T) plus Ctx in patients (pts) with pretreated HER2+metastatic (met) breast cancer (MBC).
    Escriva, Santiago
    Im, Seock-Ah
    Cardoso, Fatima
    Cortes, Javier
    Curigliano, Giuseppe
    Gradishar, William John
    Pegram, Mark D.
    Wright, Gail Lynn Shaw
    Levy, Christelle
    De laurentiis, Michelino
    Ferrero, Jean-Marc
    Bahadur, Shakeela Wazeen
    Kim, Sung-Bae
    Petrakova, Katarina
    Riseberg, David A.
    Yardley, Denise A.
    Edlich, Sutton
    Hong, Sam
    Rock, Edwin P.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase 3 SOPHIA study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in patients (pts) with HER2+metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis
    Rugo, Hope
    Im, Seock-Ah
    Cardoso, Fatima
    Cortes, Javier
    Curigliano, Giuseppe
    Musolino, Antonino
    Pegram, Mark D.
    Bachelot, Thomas
    Wright, Gail S.
    Saura, Cristina
    Escriva-de-Romani, Santiago
    De laurentiis, Michelino
    Schwartz, Gary N.
    Pluard, Timothy
    Ricci, Francesco
    Gwin, William, III
    Levy, Christelle
    Brown-Glaberman, Ursa
    Ferrero, Jean-Marc
    de Boer, Maaike
    Kim, Sung-Bae
    Petrakova, Katarina
    Yardley, Denise A.
    Freedman, Orit
    Jakobsen, Erik H.
    Gal-Yam, Einav Nili
    Yerushalmi, Rinat
    Fasching, Peter A.
    Ashley, Emily
    Hong, Shengyan
    Rosales, Minori
    Gradishar, William J.
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Infusion related reactions in the phase 3 SOPHIA trial of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with pretreated HER2+metastatic breast cancer
    Cortes, Javier
    Cardoso, Fatima
    Curigliano, Giuseppe
    Gradishar, William J.
    Im, Seock-Ah
    Rugo, Hope S.
    Bahadur, Shakeela W.
    Falcone, Alfredo
    Murillo, Serafin Morales
    Riseberg, David A.
    Musolino, Antonino
    Feinstein, Trevor M.
    Abreu, Miguel H.
    Im, Young-Hyuck
    Novik, Yelena
    Pluard, Timothy
    Salazar, Lupe G.
    Berardi, Rossana
    Pop, Viorela
    Hong, Shengyan
    Jacobs, Kenneth
    Rock, Edwin
    Pegram, Mark D.
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Health-related quality of life for margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+metastatic breast cancer
    Cardoso, Fatima
    Cortes, Javier
    Gradishar, William
    Im, Seock-Ah
    Pegram, Mark D.
    Rugo, Hope S.
    Wright, Gail S.
    De laurentiis, Michelino
    Levy, Christelle
    Ferrero, Jean-Marc
    Mansi, Janine
    Oyola, Raul
    Ricci, Francesco
    Jakobsen, Erik H.
    Uziely, Beatriz
    Egle, Daniel
    Giagounidis, Aristoteles
    Williams, Kirstin
    Hong, Shengyan
    Rock, Edwin
    Curigliano, Giuseppe
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results
    Gradishar, William J.
    Im, Seock-Ah
    Cardoso, Fatima
    Cortes, Javier
    Curigliano, Giuseppe
    Pegram, Mark D.
    Musolino, Antonino
    Berardi, Rosanna
    De laurentiis, Michelino
    Bahadur, Shakeela W.
    Im, Young-Hyuck
    Lynch, Cynthia
    Novik, Yelena
    Edlich, Sutton
    Rock, Edwin
    Hong, Shengyan
    Rugo, Hope S.
    CANCER RESEARCH, 2020, 80 (04)
  • [7] Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis
    Rugo, Hope S.
    Im, Seock-Ah
    Cardoso, Fatima
    Cortes, Javier
    Curigliano, Giuseppe
    Pegram, Mark D.
    Musolino, Antonino
    Bachelot, Thomas
    Wright, Gail S.
    De laurentiis, Michelino
    Kaufman, Peter A.
    Pluard, Timothy
    Ricci, Francesco
    Salazar, Lupe G.
    Yardley, Denise A.
    Edlich, Sutton
    Hong, Shengyan
    Rock, Edwin
    Gradishar, William J.
    CANCER RESEARCH, 2020, 80 (04)
  • [8] SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) plus chemotherapy (C) versus trastuzumab (T) plus C in patients (pts) with HER2+metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
    Rugo, Hope S.
    Im, Seock-Ah
    Wright, Gail Lynn Shaw
    Escriva-de-Romani, Santiago
    DeLaurentiis, Michelino
    Cortes, Javier
    Bahadur, Shakeela Wazeen
    Haley, Barbara B.
    Oyola, Raul H.
    Riseberg, David A.
    Musolino, Antonino
    Cardoso, Fatima
    Curigliano, Giuseppe
    Kaufman, Peter A.
    Pegram, Mark D.
    Edlich, Sutton
    Hong, Sam
    Rock, Edwin P.
    Gradishar, William John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [10] Expanding treatment options for patients with HER2+metastatic breast cancer with margetuximab plus chemotherapy: a case report series
    Mahtani, Reshma
    Harpalani, Natasha
    Yan, Fengting
    Phiel, Kristen
    Kovalenko, Iuliia
    FRONTIERS IN ONCOLOGY, 2024, 14
12345